Transcarent will acquire Accolade for $7.03 per share in cash or $621 million in total. The transaction is expected to close during the 2025 second-quarter after gaining approval from Accolade ...

Boston Scientific recalls pacemakers due to battery issues causing safety mode activation linked to 4 deaths and 2,557 serious injuries, FDA reports.

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Transcarent, a healthcare platform for self-insured ...

Transcarent, the One Place for Health and Care, and Accolade (ACCD) announced that they have entered into a definitive agreement under which Transcarent will acquire Accolade for $7.03 per share in ...

Health benefits platform Accolade made its debut on the public market Thursday and opened trading about 59% above its set price. Accolade set the pricing of its initial public offering of 10 million ...

Digital health startup Transcarent on Tuesday announced it completed its acquisition of Accolade in a deal valued at roughly $621 million. Transcarent first announced the acquisition in January, and ...

Health benefits platform Accolade is expanding into primary care with plans to acquire PlushCare in a deal valued at $450 million. Under the terms of the agreement, the purchase price of up to $450 ...

Transcarent agreed to buy Accolade Inc (NASDAQ:ACCD) Wednesday for $621 million. The purchase price works out to $7.03 per share in cash. Accolade is a Personalized Healthcare company that offers ...

Health benefits platform company Accolade is expanding its offerings to add two personalized services with an emphasis on mental health, the company announced Tuesday. The offerings will be provided ...

Health benefits platform Accolade has signed a definitive agreement to acquire virtual primary care company PlushCare for $450 million, according to a Friday statement. The combined companies plan to ...